Vasomune Therapeutics, Inc. is a privately owned early phase biopharmaceutical organization creating the subsequent generation of treatments to utilize the body's capacity to protect against disease. The firm is moving in the immediate future to the clinic with an innovative therapeutic strategy for COVID-19 that includes focusing on a signaling molecule in the vasculature, which is accountable for regulating barrier defense and enhancing endothelial stability.